Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 4/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6097633 | 0.88 | MEN1 (0.53) | BCL2MCL1MEN1NPC1RAB9A | |
| SCHEMBL3927600 | 0.88 | MEN1 (0.53) | BCL2MCL1MEN1NPC1RAB9A | |
| SCHEMBL14274532 | 0.85 | MEN1 (0.52) | BCL2MCL1ROCK1MEN1NPC1 | |
| SCHEMBL17602263 | 0.83 | MEN1 (0.56) | BCL2MCL1ROCK1MEN1NPC1 | |
| SCHEMBL21245229 | 0.83 | BCL2 (0.48) | BCL2MCL1MEN1NPC1RAB9A | |
| SCHEMBL4191518 | 0.82 | MEN1 (0.54) | BCL2MCL1ROCK1MEN1NPC1 | |
| SCHEMBL27587634 | 0.82 | BCL2 (0.56) | BCL2MCL1SRD5A2PPARDPPARA | |
| SCHEMBL5988329 | 0.80 | HTR2C (0.57) | MCL1MEN1KMT2A | |
| SCHEMBL21245824 | 0.80 | HTR2C (0.57) | MCL1MEN1KMT2A | |
| SCHEMBL3193186 | 0.80 | MAPK14 (0.61) | ROCK1MEN1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230124268-A1 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND METHODS FOR USE OF THE SAME | UNIV INDIANA TRUSTEES (US) | 2023-04-20 | — | — | US | disclosed |
| US-11584766-B2 | Nicotinamide phosphoribosyltransferase inhibitors and methods for use of the same | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210070784-A1 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND METHODS FOR USE OF THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2021-03-11 | — | — | US | disclosed |
| WO-2019153007-A2 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND METHODS FOR USE OF THE SAME | THE BOARO OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070784-A1 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND METHODS FOR USE OF THE SAME | NAMPT, NNT, NAPRT | BCL2 4673/4885MCL1 4515/4885ROCK1 1250/4885 |
| US-20230124268-A1 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND METHODS FOR USE OF THE SAME | NAMPT, NNT, NAPRT | BCL2 4673/4885MCL1 4515/4885ROCK1 1250/4885 |
| US-11584766-B2 | Nicotinamide phosphoribosyltransferase inhibitors and methods for use of the same | NAMPT, NNT, NAPRT | BCL2 4673/4885MCL1 4515/4885ROCK1 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.